Please assess the completion status of the following clinical trial:

Trial Title: DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Diagnosis of DLBCL as documented by medical records and with histology based on criteria established by the World Health Organization~  * subtyping is required for DLBCL~ * c-myc+ defined as presence of c-myc breaks by karyotype/FISH and/or IHC ≥ 40%; this includes double hits (with bcl-2 breaks found using cytogenetics/FISH) and/or double expressors (with bcl-2 protein expression ≥ 70% by IHC); increased copy number in itself is not considered positivity for c-myc~* No prior therapy for diagnosis of DLBCL with exception of steroids~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2 (Appendix B)~* Life expectancy of at least 6 months~* No history of medication dependent diabetes mellitus~* No evidence of acute or chronic metabolic acidosis (baseline venous lactate ≤ 4)~Exclusion Criteria~* Patient already on any class of anti-diabetic medication including metformin, insulin analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies or clear need for therapeutic intervention based on fasting blood glucose~* Known histological transformation from indolent non-Hodgkin Lymphoma (iNHL) or chronic lymphocytic leukemia (CLL) to an aggressive form of non-Hodgkin's lymphoma (NHL) (ie, Richter transformation)~* Burkitt and/or precursor lymphoblastic leukemia/lymphoma.~* Presence of known intermediate- or high-grade myelodysplastic syndrome~* History of an active of treated non-lymphoid malignancy within the last 3 years excluding basal cell and squamous cell skin cancers~* Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug.~* Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)~* Renal insufficiency with creatinine \> 1.5 x upper limit of normal (ULN) OR creatinine clearance of \< 45 ml/min as calculated by the Cockcroft-Gault method~* CNS or leptomeningeal involvement of lymphoma~* HIV positive~* Ongoing inflammatory bowel disease~* Ongoing alcohol or drug addiction~* Pregnancy or breastfeeding~* History of prior allogeneic bone marrow progenitor cell or solid organ transplantation -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm, open label (Type: EXPERIMENTAL): Metformin added to standard of care treatment for all patients

Based on this trial design, predict the completion outcome and termination type (if applicable).